squamous cell lung cancer
Conditions
Interventions
Nedaplatin 80-100mg/m2 day 1, q4w until disease progression or intolerable toxicity.
Sponsors
Shizuoka Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically proven squamous cell lung cancer. 2) Chemo-naive clinical stage IIIB/IV or relapsed patients. 3) Age of 75 years or older. 4) Performance status (PS) of 0-1 in ECOG criteria. 5) Adequate organ functions. 6) With measurable lesion. 7) Life expectancy more than 3 months. 8) Written informed consent.
Exclusion criteria
Exclusion criteria: 1) Patients with brain metastasis in need of steroid or anticonvulsant. 2) Less than 4 weeks after curative radiotherapy to primary lesion or less than 2 weeks after palliative radiotherapy. 3) History of active double cancer. 4) Patients with superior vena cava syndrome. 5) Uncontrollable pleural effusion, pericardial effusion or ascites. 6) History of uncontrollable hypertension, diabetes mellitus, active angina pectoris, active gastrointestinal hemorrhage, recent cardiac incompetence, recent myocardial infarction and active viral infection (except viral hepatitis). 7) Interstitial shadow of UIP (usual interstitial pneumonia) pattern on chest CT. 8) History of severe drug allergy. 9) History of severe psychiatric disease. 10) Patients whose participation in the trial is judged to be inappropriate by the attending doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Progression free survival, Adverse events | — |
Countries
Japan
Contacts
Public ContactTetsuhiko Taira
Shizuoka Cancer Center Division of Thoracic Oncology
Outcome results
None listed